David Felson awarded Carol Nachman Prize for Rheumatology

May 12, 2017

The 201David Felson7 Carol Nachman Prize for Rheumatology was awarded to David T. Felson, MD, MPH, Professor of Medicine and Epidemiology at BUSM and BUSPH.

David T. Felson (SPH’84), Professor of Epidemiology at the School of Public Health and of Medicine at the School of Medicine, has been awarded the 2017 Carol Nachman Prize for Rheumatology.

The prize is the most prestigious international award for research in rheumatology. Felson received the award on May 12 in Wiesbaden, Germany.

Dr. Felson’s research interests include understanding how to prevent and treat osteoarthritis (OA)—also known as degenerative joint disease, or “wear and tear” arthritis. He is studying whether treatments for rheumatic diseases are effective and, particularly in osteoarthritis, identifying risk factors for disease, testing treatments, and characterizing MRI features of normal knees and knees with pain. He also studies outcome measurement (tests that objectively determine a patients’ baseline function at the beginning of treatment) in rheumatic disease, and has focused in this work on rheumatoid arthritis trials.

Felson led a series of major studies to identify prevalence, impact, and risk factors for knee OA. In the Framingham Osteoarthritis Study, his group first documented that obesity increased the risk of OA and that weight loss could lessen that risk. The first to introduce magnetic resonance imaging in large-scale studies, his group discovered that meniscal tears and other structural pathology were present in most middle-aged and older persons regardless of knee pain. He inaugurated the study of structural correlates of joint pain, identifying for the first time that in OA, synovitis and bone marrow lesions cause pain; these structural findings have now emerged as targets of treatment. Recent work from his group suggests that chronic alterations in the nervous system that enhance pain sensitivity affect most patients with OA pain.

Working with the FDA and rheumatology organizations, he also led the effort to standardize clinical trial outcome measurement in rheumatoid arthritis, creating the first core set of outcomes and coming up with the American College of Rheumatology definition of improvement (ACR20). This outcome standardization made it possible for the first time to gauge the relative efficacy of new drugs such as TNF inhibitors.

The recipient of numerous awards, Felson was the first non-basic scientist recipient of the Kunkel Young Investigator Award from the American College of Rheumatology, and from this same organization, he received its inaugural Clinical Research Award.

Felson graduated from Harvard College and received his MD from Johns Hopkins University. After a residency in internal medicine at Case Western Reserve, he trained in rheumatology at Boston University and received his MPH in epidemiology from SPH. He joined the BU faculty in 1984, became a professor in 1994, and was appointed chair of clinical epidemiology in 2001.  He is Director of Training and Education for the BU Clinical Translational Science Institute and Director of Clinical Epidemiology at Boston Medical Center.

View all posts